VANCOUVER, British Columbia, July 18, 2005 (PRIMEZONE) -- ProtoKinetix, Inc. (OTCBB:PKTX) announces that tests repeated by ProteoCell Biotechnologies, using higher concentrations of AFGP, in both monomeric and dimeric forms, show a substantial increase in cell survival over an extended period of time. These results using 5 mg./ml. at a temperature of -3 degrees C produced an 85% survivability over a 20-hour period. The Company has clearly demonstrated a correlation between concentration size and the length of survival time. Even at these very low levels of dosage size, ProtoKinetix has produced very real increases in both the percent of cell survival and the length of survival time.
Survivability of this magnitude, with these exceptionally delicate heart cells, should translate into even greater gains with tissues and organs. The shelf life of a human heart transported under ideal conditions is currently only 5-hours. This new data shows that the Company has achieved their initial objective of over 90% survival rate for a 16-hour period and will continue to test the full potential of these exciting molecules.
About ProtoKinetix:
ProtoKinetix, Inc. is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial market place will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors,
Dr. John Todd, President